Advancing the Discovery & Development of Peptide Drugs with Novel Screening, Chemistry, Formulation & CMC to Improve Permeability, Bioavailability & Efficacy Across All Diseases
Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.
Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore:
- Novel computational tools
- Optimize analytical assays
- Formulating cell-specific delivery methods
- DMPK translatability towards clinical success of peptide therapies
Join 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.
Attending Companies Include